Tezosentan in Patients With Pulmonary Arterial Hypertension

Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Demonstrate That a Single Infusion of Tezosentan Has Minimal Effect on Blood Pressure in Patients With Pulmonary Arterial Hypertension, Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or a Combination of Both.

Multicenter, double-blind, randomized, placebo-controlled, cross-over study to demonstrate that a single infusion of tezosentan has minimal effect on blood pressure in patients with pulmonary arterial hypertension, treated with endothelin receptor antagonists, phosphodiesterase-5 inhibitors or a combination of both.

Study Overview

• Status: Terminated
• Conditions: Pulmonary Arterial Hypertension
• Intervention / Treatment: Other: Placebo; Drug: ACT-050089

• Study Type: Interventional
• Enrollment (Actual): 2
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Clamart, France, 92141
    • Hôpital Antoine Béclère
• Japan
  • Osaka, Japan, 565-0871
    • Osaka University Hospital
  • Osaka, Japan, 565-8865
    • National Cardiovascular Center
  • Shinjuku-Ku, Japan, 160-8582
    • Keio University Hospital
• United States
  • Texas
    • Houston, Texas, United States, 77030
      • Baylor College of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria :

1. Signed informed consent prior to initiation of any study-mandated procedure
2. Male and female patients 18 years of age or older

3. Patients with PAH according to one of the following subgroups of the Dana Point Classification Group 1:

   • Idiopathic, or
   • Heritable, or
   • Associated with connective tissue disease

4. Documented hemodynamic diagnosis of PAH by right heart catheterization (not part of study mandated procedures):

   • Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and
   • Resting mean pulmonary vascular resistance (PVR) ≥ 240 dyn•s•cm 5 and
   • Pulmonary capillary wedge pressure ≤ 15 mmHg
5. Modified NYHA functional class II-III
6. Patients on treatment with ERAs, PDE-5 inhibitors or a combination of both, if used for at least 3 months prior to Visit 1 and dosing kept stable for at least 28 days prior to Visit 1.

Exclusion Criteria :

1. Patients with PAH in Dana Point Classification Groups 2-5, and PAH Group 1 subgroups not covered by inclusion criterion No. 3
2. Patients with sitting SBP < 100 mmHg
3. Patients with sitting DBP < 60 mmHg
4. Patients with body weight < 50 kg (110 lbs)
5. Patients with clinically significantly elevated liver enzymes (AST, ALT and/or alkaline phosphatase > 3 times upper limit)
6. Patients with clinically significant chronic renal insufficiency (serum creatinine >2.5mg/dL / 221 µmol/L)
7. Patients with moderate or severe hepatic impairment (Child-Pugh B and C)
8. Patients who have received prostacyclin (epoprostenol) or prostacyclin analogs (e.g., treprostinil, iloprost and beraprost) within 28 days of Visit 1
9. Patients who have received any investigational drugs within 28 days of Visit 1
10. Patients who have received cyclosporine A (CsA) or tacrolimus within 28 days of Visit 1
11. Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with the study
12. Life expectancy less than 12 months
13. Females who are lactating or pregnant (positive pre-treatment pregnancy tests) (serum test at Screening and urine test on Visit 1 and 2) or females who are not using a reliable method of birth control (failure rate less than 1% per year) during the study and for at least one month after last administration of study drug
14. Known hypersensitivity to any of the excipients of the drug formulation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1; Placebo at visit 1, tezosentan at visit 2	Other: Placebo; Matching placebo; Drug: ACT-050089; 5 mg/h intravenously, Tezosentan
Experimental: 2; Tezosentan at visit 1, placebo at visit 2	Other: Placebo; Matching placebo; Drug: ACT-050089; 5 mg/h intravenously, Tezosentan

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Absolute change in supine SBP from Baseline to 30 minutes at each visit (Visit 1 and Visit 2) - in mmHg	30 days

Secondary Outcome Measures

Outcome Measure	Time Frame
Absolute change in heart rate from Baseline to 30 minutes at each visit (Visit 1 and Visit 2) - in bpm	30 days

Collaborators and Investigators

• Sponsor: Idorsia Pharmaceuticals Ltd.

Study record dates

Study Major Dates

• Study Start: September 1, 2010
• Primary Completion (Actual): December 1, 2010
• Study Completion (Actual): September 1, 2011

Study Registration Dates

• First Submitted: March 25, 2010
• First Submitted That Met QC Criteria: March 25, 2010
• First Posted (Estimate): March 26, 2010

Study Record Updates

• Last Update Posted (Actual): July 9, 2018
• Last Update Submitted That Met QC Criteria: July 6, 2018
• Last Verified: July 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Lung Diseases; Hypertension, Pulmonary; Hypertension; Pulmonary Arterial Hypertension; Familial Primary Pulmonary Hypertension
• Other Study ID Numbers: AC-051-207